NCT01731119View on ClinicalTrials.gov

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
SchizophreniaSchizoaffective DisorderSchizophreniform DisorderPsychosis NOSAutistic DisorderAsperger SyndromeChild Development Disorders, PervasiveBipolar I DisorderBipolar II DisorderMood Disorder NOSSevere Major Depression With Psychotic FeaturesSingle Episode Major Depression Without Psychotic SymptomsSevere Mood Disorder With Psychotic Features
Interventions
DRUG

Latuda©

All subjects will be started on 20-40mg of Latuda© at night (suggested intake with food). Subsequently, the dose may be increased as clinically indicated and based on tolerability every 7 days by 20-40mg to a maximum of 160mg per day with food which may be given as a single or twice daily dose depending on participant's preference. The maintenance dose will be determined solely by the clinician in accordance with the best interests of each participant.

Trial Locations (1)

27517

University of North Carolina, Chapel Hill

All Listed Sponsors
collaborator

Foundation of Hope, North Carolina

OTHER

lead

University of North Carolina, Chapel Hill

OTHER

NCT01731119 - Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents | Biotech Hunter | Biotech Hunter